Summary of study ST000783

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000569. The data can be accessed directly via it's Project DOI: 10.21228/M8437T This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000783
Study TitleAbsolute Quantification of 180 metabolites in serum from african american and european american in prostate cancer and case control samples
Study SummaryMetabolite concentrations were obtained in prostate cancer and case control plasma samples from AA and EA individuals using the AbsoluteIDQ kit p180 (Biocrates Life Science AG, Austria) according to the manufacturer’s instructions. The analysis was performed using a QTRAP 6500 LC/MS/MS System (AB SCIEX, USA) equipped with an electrospray ionization source, Agilent G1367B autosampler and the Analyst 1.51 software (AB SCIEX, USA).
Baylor College of Medicine
Last NameSreekumar
First NameArun
AddressOne Baylor Plaza, Houston, TX, 77030, USA
Submit Date2017-05-18
Analysis Type DetailLC-MS
Release Date2019-07-17
Release Version1
Arun Sreekumar Arun Sreekumar application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000569
Project DOI:doi: 10.21228/M8437T
Project Title:Serum metabolomics study of prostate cancer for african american
Project Summary:We studied the metabolome in a group of AA and EA of prostate cancer and case control plasma.
Institute:Baylor College of Medicine
Last Name:Sreekumar
First Name:Arun
Address:One Baylor Plaza, Houston, TX, 77030, USA


Subject ID:SU000806
Subject Type:human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human


Subject type: human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Status RACE
SA04263119622Case control AA
SA04263219843Case control AA
SA04263319869Case control AA
SA04263419224Case control AA
SA04263518717Case control AA
SA04263618489Case control AA
SA04263718664Case control AA
SA04263820049Case control AA
SA04263918783Case control AA
SA04264020070Case control AA
SA04264120323Case control AA
SA04264220361Case control AA
SA04264320752Case control AA
SA04264420319Case control AA
SA04264520103Case control AA
SA04264618415Case control AA
SA04264720078Case control AA
SA04264820099Case control AA
SA04264920051Case control AA
SA04265018665Case control AA
SA04265118137Case control AA
SA04265218140Case control AA
SA04265318013Case control AA
SA04265418014Case control AA
SA04265518004Case control AA
SA04265617962Case control EA
SA04265718580Case control EA
SA04265818559Case control EA
SA04265917893Case control EA
SA04266018638Case control EA
SA04266118154Case control EA
SA04266218072Case control EA
SA04266318062Case control EA
SA04266418796Case control EA
SA04266518035Case control EA
SA04266618702Case control EA
SA04266718077Case control EA
SA04266817848Case control EA
SA04266919237Case control EA
SA04267018265Case control EA
SA04267118402Case control EA
SA04267218277Case control EA
SA04267318323Case control EA
SA04267418404Case control EA
SA04267518285Case control EA
SA04267619464Case control EA
SA04267719255Case control EA
SA04267818250Case control EA
SA04267918463Case control EA
SA04268018225Case control EA
SA04268119144Prostate cancer AA
SA04268219678Prostate cancer AA
SA04268319924Prostate cancer AA
SA04268419502Prostate cancer AA
SA04268519515Prostate cancer AA
SA04268619901Prostate cancer AA
SA04268719838Prostate cancer AA
SA04268819766Prostate cancer AA
SA04268917985Prostate cancer AA
SA04269018515Prostate cancer AA
SA04269118517Prostate cancer AA
SA04269218183Prostate cancer AA
SA04269318414Prostate cancer AA
SA04269418302Prostate cancer AA
SA04269518331Prostate cancer AA
SA04269618970Prostate cancer AA
SA04269718538Prostate cancer AA
SA04269818939Prostate cancer AA
SA04269918893Prostate cancer AA
SA04270015298Prostate cancer AA
SA04270118567Prostate cancer AA
SA04270218177Prostate cancer AA
SA04270317585Prostate cancer EA
SA04270419655Prostate cancer EA
SA04270518109Prostate cancer EA
SA04270619001Prostate cancer EA
SA04270718865Prostate cancer EA
SA04270818228Prostate cancer EA
SA04270919023Prostate cancer EA
SA04271018669Prostate cancer EA
SA04271118596Prostate cancer EA
SA04271218262Prostate cancer EA
SA04271318542Prostate cancer EA
SA04271418557Prostate cancer EA
SA04271519084Prostate cancer EA
SA04271619093Prostate cancer EA
SA04271719243Prostate cancer EA
SA04271819575Prostate cancer EA
SA04271918130Prostate cancer EA
SA04272019189Prostate cancer EA
SA04272119168Prostate cancer EA
SA04272219113Prostate cancer EA
SA04272319157Prostate cancer EA
SA04272419648Prostate cancer EA
Showing results 1 to 94 of 94


Collection ID:CO000800
Collection Summary:Clinically annotated ancestry verified serum samples from the National Cancer Institute.
Sample Type:Blood


Treatment ID:TR000820
Treatment Summary:NA

Sample Preparation:

Sampleprep ID:SP000813
Sampleprep Summary:Briefly, 10 μl of undiluted plasma sample from each patient or control individual was placed in individual wells of a 96 well plate provided by the manufacturer. Samples were dried at room temperature using a nitrogen evaporator drying unit for 30 mins. Following this, 20 μl of 5% phenylisothiocyanate (PITC) reagent was added to the dried plasma spots and incubated for 20 min at RT. The plate was again dried under the nitrogen evaporator for 60 mins. Next, 300 μl of 5 mM ammonium acetate in methanol was added to each well and the mixture was incubated on a shaker (450 rpm) for 30 mins. The plate was then centrifuged at 100 g for 2 min resulting in a volume of ~ 250 μl sample in the plate (labeled as Flow injection or FIA plate). 150 μl of the sample was subsequently transferred from the FIA plate into a second plate (termed LC-MS plate). In total, all the samples were analyzed in three batches, each containing one FIA and LC-MS plate, respectively. 150 μl HPLC grade water was added to the LC-MS plate to make up the volume to 300 ul. In parallel, 500 μl of mass spectrometry injection solvent (stock solution provided by Biocrates was diluted in methanol) was added to the FIA plate. The LC-MS plate was analyzed using Multiple Reaction Monitoring post LC-MS fractionation. The FIA plate was stored at 4°C until the LC-MS plate was completed assayed.

Combined analysis:

Analysis ID AN001239
Analysis type MS
Chromatography type None (Direct infusion)
Chromatography system None
Column none
MS instrument type Triple quadrupole
MS instrument name AB Sciex 6500 QTRAP LC-MS/MS
Units uM


Chromatography ID:CH000866
Chromatography Summary:Flow injection coupled to MRM was used to measure mono-unsaturated glycerophosphophocholines in samples in the FIA plate. For flow injection analysis, 20 μl of sample was injected directly into the MS at a flow rate of 30 μl/min in mobile phase.
Instrument Name:None
Column Name:none
Chromatography Type:None (Direct infusion)


MS ID:MS001133
Analysis ID:AN001239
Instrument Name:AB Sciex 6500 QTRAP LC-MS/MS
Instrument Type:Triple quadrupole